SD, IL-13 Production Rate in IPF

A Open-label, Multicenter Study, With a Single Intravenous Dose of QAX576 to Determine IL-13 Production in Patients With Idiopathic Pulmonary Fibrosis

The purpose of this study is to investigate how QAX576 affects levels of interleukin 13 (IL-13) in patients with idiopathic pulmonary fibrosis (IPF).

Inclusion Criteria:

• Men and women between the ages of 40 and 80 years with a confirmed diagnosis of idiopathic pulmonary fibrosis
• Both men and women must be on non-childbearing potential. Additional information regarding this requirement is available at screening.
• Capability to meet certain lung function tests at screening
• Non-smokers
• No participation in another clinical study within 4 weeks of study start.

Exclusion Criteria:

• Certain medical conditions may exclude candidates from participation.
• Blood loss or donation of 400 mL or more within 2 months of study start Significant illness (other than respiratory) within 2 weeks of study start
• Past medical personal or close family history of clinically significant ECG abnormalities
• Connective tissue disorders
• Active infection or history of systemic parasitic infection
• Known hypersensitivity to the drug.
• History of immunocompromise, including a positive HIV test result.
• History of drug or alcohol abuse within 12 months of study start
• Any condition that may compromise patient safety